Introduction. It was found that vitamin D may have a direct effect on adipocyte differentiation and metabolism and might be involved in the glucose regulation of insulin secretion, as suggested from the discovery of a nuclear localization of 1,25-(OH)2D3 in pancreatic islets. In recent years, several polymorphisms in the VDR gene which are able to alter the activity of VDR protein have been described. The BsmI and FokI polymorphisms were described in relation to obesity and type 2 diabetes. The aim of the study was to find whether there are associations between BsmI and FokI polymorphisms and anthropometric (BMI, WHR, BP) and biochemical parameters describing metabolic syndrome. Materials and methods. Studied were 176 randomly selected men aged 25–65 years (mean: 51.99 years) with a mean BMI of 28.06 kg/m2. Two polymorphisms of the VDR gene (FokI and BsmI) were explored using the PCR-RFLP method. Serum glucose, insulin, total cholesterol, LDL, HDL, and TG were measured using commercially available kits. Results. It was found that BB carriers tend to have higher BMI (29.00 ± 3.74 versus 26.81 ± 3.76, p = 0.024) and waist circumference (101.79 ± 10.59 versus 96.23 ± 10.35, p = 0.014) compared with the bb genotypes. Similarly, FF and Ff carriers had higher fasting insulin levels than the ff genotypes (12.30 ± 10.26 versus 9.76 ± 5.88, p = 0.001 and 9.76 ± 5.88 vs. 6.35 ± 2.64, p = 0.008), and lover cHDL levels in comparison to ff genotypes (52.28 ± 10.02 versus 60.63 ± 16.58, p = 0.015 and 53.70 ± 12.03 versus 60.63 ± 16.58, p = 0.032. Besides these, no significant differences were found. Conclusions. The BsmI VDR polymorphism seems to influence BMI, while the FokI VDR polymorphism appears to affect insulin sensitivity and serum cHDL level.
Objective Adiponectin plays a significant role in the modulation of glucose tolerance and insulin sensitivity. We attempted to evaluate the relationship between adiponectin level and parameters of the menopausal metabolic syndrome: body mass index, waist-to-hip ratio, lipid profile and insulin resistance indices. Subjects and methods Thirty-two women and ten men aged 40–63 years were included. The percentage of body fat and of abdominal fat deposits were measured with dual-energy X-ray absorptiometry. Serum adiponectin, tumour necrosis factor-α (TNFα) and leptin were measured with commercially available radioimmunoassay kits. To exclude the influence of nutritional factors on adiponectin secretion, diet content was analysed in the preceding three days. Results Postmenopausal non-obese women had a non-significantly lower level of adiponectin compared with premenopausal women of corresponding body mass. Serum adiponectin level was significantly lower in postmenopausal obese women than in non-obese women (p = 0.0023). Men with similar age and body mass to the women had the lowest level of adiponectin (p = 0.06). Three months of estrogen replacement therapy in women with surgical menopause did not significantly change the serum level of adiponectin. We found a negative correlation of adiponectin with leptin, insulin resistance index and total cholesterol, and a positive correlation with high-density lipoprotein cholesterol. Adiponectin level was negatively correlated with free testosterone, but we did not find such a relationship with estradiol. There was no correlation of adiponectin level with TNFα; however, serum TNFα correlated positively with leptin. The dietary analysis showed no differences between the diets of obese and non-obese women over the preceding three days. Moreover, mean diastolic and systolic blood pressures were noted to be significantly lower in premenopausal women than in postmenopausal non-obese women (p = 0.05). Conclusions Our results suggest that adiponectin could be a marker of risk for developing menopausal metabolic syndrome. Moreover, it is possible that sex steroids have an influence on adiponectin secretion.
Objective: The contribution of genetic factors to the development of menopausal obesity has been widely recognized. Peroxisome proliferator-activated receptor gamma (PPARγ) is involved in adipocyte differentiation and has been suggested to influence insulin sensitivity. The aim of this study was to evaluate the frequency of Pro12Ala PPARγ polymorphism and its association with body mass index (BMI) and metabolic syndrome parameters in postmenopausal Polish women. Material and Methods: The study was performed in 318 postmenopausal women aged 50–60 years randomly selected from the Wrocław city population with BMI ranging from 17.5 to 46.38 kg/m2 (mean BMI 27.5±4.78 kg/m2). Anthropometric parameters, body composition (total body fat, android and gynoid deposits, using DXA) and biochemical parameters (lipid profile, glucose, and insulin levels) were measured and QUICKI was calculated. PPARγ genotyping was performed by PCR and minisequencing using an ABI 310 sequencer (Applied Biosystems). Results: The Pro12Ala genotype was found in 26% of the women, but Ala12Ala only in 4%. Metabolic syndrome was recognized in 16% of all the women, 14% of the women with Pro12Pro genotype, 21% of the Pro12Ala carriers, and 14% of the women with the Ala12Ala variant. Obese women with at least one Ala allele (X/Ala genotype) showed higher serum levels of total cholesterol (265.7±44.5 mg/dl vs. 233.2±38.1 mg/dl, p<0.001), LDL cholesterol (171.8±37.8 mg/dl vs. 143.7±34.8 mg/dl; p<0.001), and triglycerides (149.4±55.2 mg/dl vs. 126.8±54.2 mg/dl, p<0.05) compared with the women with the Pro12Pro genotype. Conclusions:The Pro12Ala PPARγ polymorphism does not seem to be associated with BMI or metabolic syndrome parameters in postmenopausal Polish women, although the X/Ala genotype seems to predispose to a less favorable lipid profile in this population.